The not-so-terrible challenge for future trials of COVID-19 therapeutics
Several companies, including Pfizer, are developing antiviral drugs that could halt the progression of COVID-19 symptoms or prevent the onset of disease for close contacts of people with infections. Theoretically, the therapeutics would be another tool used to fight the coronavirus alongside vaccines.
Former Food and Drug Administration Commissioner Scott Gottlieb is confident there will be some successes, noting that the coronavirus isn't "a hard virus to drug in terms of how it replicates." But there is a bit of a race against the clock on this issue, although the reason for that probably won't be the worst thing you've heard since the pandemic began.
It's becoming more difficult to find "virus naive" patients in the United States, Gottlieb said during an appearance on MSNBC's Squawk Box on Monday. Because so many people have either been vaccinated or had a previous infection, it's increasingly challenging to find enough people who don't have some form of immunity to enroll in trials to determine the efficacy of the drug treatments. Watch Gottlieb's explanation below.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Parmigianino: The Vision of St Jerome – masterpiece given 'new lease of life'
The Week Recommends 'Spectacularly inventive' painting is back on display at the National Gallery
By The Week UK Published
-
5 unidentifiable cartoons about drones over New Jersey
Cartoons Artists take on national priorities, national security, and more
By The Week US Published
-
Carry-On: Taron Egerton's airport thriller is 'unexpectedly watchable'
Talking Point Netflix action movie makes a few 'daft swerves' – but is a 'thoroughly enjoyable' watch
By The Week UK Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published